INVESTIGATION REMINDER: The Schall Law Firm Encourages Investors in ChemoCentryx, Inc. with Losses of $100,000 to Contact the FirmBusiness Wire • 03/03/22
INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in ChemoCentryx, Inc. with Losses of $100,000 to Contact the FirmBusiness Wire • 03/02/22
ChemoCentryx, Inc. (CCXI) CEO Thomas Schall on Q4 2021 Results - Earnings Call TranscriptSeeking Alpha • 03/02/22
ChemoCentryx Reports Fourth Quarter and Full Year 2021 Financial Results and Recent HighlightsGlobeNewsWire • 03/01/22
ChemoCentryx to Hold Fourth Quarter and Full Year 2021 Financial Results Conference Call on Tuesday, March 1, 2022GlobeNewsWire • 02/23/22
ChemoCentryx to Participate in the 11th Annual SVB Leerink Global Healthcare ConferenceGlobeNewsWire • 02/09/22
SHAREHOLDER ALERT: Rigrodsky Law, P.A. Announces Investigation of ChemoCentryx, IncNewsfile Corp • 02/04/22
SHAREHOLDER ALERT: Robbins LLP Investigates ChemoCentryx, Inc. (CCXI) on Behalf of ShareholdersBusiness Wire • 01/27/22
ChemoCentryx Announces EU Approval of TAVNEOS® (avacopan) for the Treatment of ANCA-Associated VasculitisGlobeNewsWire • 01/19/22
Positive Recommendation for Use of TAVNEOS™ (avacopan) in ANCA Vasculitis Adopted by European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP)GlobeNewsWire • 11/12/21